Yogesh B. Pawar - Search Results

Year	Number of Results
2010	1
2011	2
2012	5
2013	2
2015	1
2022	0

1

Phase behavior and oral bioavailability of amorphous Curcumin.

Pawar YB, Shete G, Popat D, Bansal AK. Pawar YB, et al. Eur J Pharm Sci. 2012 Aug 30;47(1):56-64. doi: 10.1016/j.ejps.2012.05.003. Epub 2012 May 15. Eur J Pharm Sci. 2012. PMID: 22609283

2

Comparative oral bioavailability advantage from curcumin formulations.

Munjal B, Pawar YB, Patel SB, Bansal AK. Munjal B, et al. Drug Deliv Transl Res. 2011 Aug;1(4):322-31. doi: 10.1007/s13346-011-0033-3. Drug Deliv Transl Res. 2011. PMID: 25788366

3

Effect of counterions on physicochemical properties of prazosin salts.

Kumar L, Meena CL, Pawar YB, Wahlang B, Tikoo K, Jain R, Bansal AK. Kumar L, et al. Among authors: pawar yb. AAPS PharmSciTech. 2013 Mar;14(1):141-50. doi: 10.1208/s12249-012-9889-x. Epub 2012 Dec 19. AAPS PharmSciTech. 2013. PMID: 23250707 Free PMC article.

4

Mechanistic insights into PEPT1-mediated transport of a novel antiepileptic, NP-647.

Khomane KS, Nandekar PP, Wahlang B, Bagul P, Shaikh N, Pawar YB, Meena CL, Sangamwar AT, Jain R, Tikoo K, Bansal AK. Khomane KS, et al. Among authors: pawar yb. Mol Pharm. 2012 Sep 4;9(9):2458-68. doi: 10.1021/mp200672d. Epub 2012 Jul 26. Mol Pharm. 2012. PMID: 22779445

5

Oral bioavailability and pharmacodynamic activity of hesperetin nanocrystals generated using a novel bottom-up technology.

Shete G, Pawar YB, Thanki K, Jain S, Bansal AK. Shete G, et al. Among authors: pawar yb. Mol Pharm. 2015 Apr 6;12(4):1158-70. doi: 10.1021/mp5008647. Epub 2015 Mar 25. Mol Pharm. 2015. PMID: 25785392

6

Novel lipid based oral formulation of curcumin: development and optimization by design of experiments approach.

Pawar YB, Purohit H, Valicherla GR, Munjal B, Lale SV, Patel SB, Bansal AK. Pawar YB, et al. Int J Pharm. 2012 Oct 15;436(1-2):617-23. doi: 10.1016/j.ijpharm.2012.07.031. Epub 2012 Jul 27. Int J Pharm. 2012. PMID: 22842624

7

Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model.

Wahlang B, Pawar YB, Bansal AK. Wahlang B, et al. Among authors: pawar yb. Eur J Pharm Biopharm. 2011 Feb;77(2):275-82. doi: 10.1016/j.ejpb.2010.12.006. Epub 2010 Dec 13. Eur J Pharm Biopharm. 2011. PMID: 21147222

8

SNEDDS curcumin formulation leads to enhanced protection from pain and functional deficits associated with diabetic neuropathy: an insight into its mechanism for neuroprotection.

Joshi RP, Negi G, Kumar A, Pawar YB, Munjal B, Bansal AK, Sharma SS. Joshi RP, et al. Among authors: pawar yb. Nanomedicine. 2013 Aug;9(6):776-85. doi: 10.1016/j.nano.2013.01.001. Epub 2013 Jan 22. Nanomedicine. 2013. PMID: 23347896

9

Bioavailability of a lipidic formulation of curcumin in healthy human volunteers.

Pawar YB, Munjal B, Arora S, Karwa M, Kohli G, Paliwal JK, Bansal AK. Pawar YB, et al. Pharmaceutics. 2012 Oct 9;4(4):517-30. doi: 10.3390/pharmaceutics4040517. Pharmaceutics. 2012. PMID: 24300368 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results